Pharmacokinetic Interactions in Combination Therapies for Acute Myeloid Leukemia

Acute myeloid leukemia is characterized by a malignant proliferation of hematopoietic progenitor cells of the myeloid lineage. The lack of differentiation of precursor cells causes their inability to function normally and the disruption of normal hematopoiesis. This review provides a brief overview of the most important pharmacological strategies that impact on acute myeloid leukemia cure rates and highlights their pharmacokinetic interactions and limitations when used in association. The widespread molecular heterogeneity of acute myeloid leukemia might lead to the identification of “druggable” targets and thus to drugs with an improved therapeutic profile. However, a great deal of focus has to be given to the identification of drug associations with a favourable pharmacokinetic profile that will ultimately contribute to the improved outcomes so cogently needed in acute myeloid leukemia.